New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 16, 2014
09:25 EDTACT, ACT, ACT, VRX, VRX, VRX, SGEN, SGEN, SGEN, REGN, REGN, REGN, MNK, MNK, MNK, INCY, INCY, INCY, GILD, GILD, GILD, CELG, CELG, CELG, BIIB, BIIB, BIIB, XLRN, XLRN, XLRNPiper Jaffray tech and biopharma analysts hold analyst/industry conference call
Technical Analyst Johnson, along with BioPharma Analysts, discuss the recent downturn in the biotech and specialty pharmaceuticals industries on an Analyst/Industry conference call to be held on April 17 at 10 am.
News For ACT;BIIB;CELG;GILD;INCY;MNK;REGN;SGEN;VRX;XLRN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
May 15, 2015
08:15 EDTREGNRegeneron target upped to $550 at Credit Suisse citing growth potential
Subscribe for More Information
08:04 EDTREGNRegeneron price target raised to $450 from $427 at JPMorgan
JPMorgan said it is "increasingly confident" in dupilumab's longer-term prospects in asthma ahead of the full Phase 2b results. The firm believes the drug's peak sales could top $4B. JPMorgan keeps a Neutral rating on Regeneron, however, saying its valuation already reflects blockbuster sales for Eylea, Praluent, sarilumab and dupilumab. It raised its price target for the name to $450 from $427.
May 14, 2015
11:11 EDTCELGAnalysts divided on significance of Celgene blood cancer drug data
Subscribe for More Information
08:50 EDTINCYIncyte data promising, says SunTrust
SunTrust believes that the data for Incyte's JAK1/PI3K combination in NHL and HL is promising. The firm says that the combo shows early signs of activity in B cell malignancies. It keeps a $120 price target and Buy rating on the shares.
May 13, 2015
17:42 EDTCELGCelgene announces over 55 blood, solid tumor cancer study presentations at ASCO
Subscribe for More Information
17:40 EDTXLRNAcceleron to present DART study data at ASCO
Acceleron Pharma, a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair, announced that data from the DART study, an ongoing phase 2 clinical trial of dalantercept in patients with advanced renal cell carcinoma will be presented at the 2015 American Society of Clinical Oncology, ASCO, Annual Meeting in Chicago, Illinois.
16:39 EDTACTAdamas Pharmaceuticals sees Namzaric launching in coming months
During its Q1 earnings report, Adamas (ADMS) stated, "In the coming months, we look forward to expanding our wholly-owned product pipeline with the initiation of a phase 2 clinical trial of ADS-5102 for a second CNS-related indication, completing enrollment in one of two ongoing phase 3 trials assessing ADS-5102 for the treatment of LID, and the U.S. launch of Namzaric by our collaborator, Actavis (ACT)."
13:12 EDTGILDSen. Sanders urges VA to break patents on Gilead hepatitis C drugs
Subscribe for More Information
07:32 EDTBIIBBiogen names Matt Griffiths as CIO
Subscribe for More Information
07:31 EDTGILDHeart Rhythm Society to hold a conference
Heart Rhythm 2015 is being held in Boston on May 13-16.
May 12, 2015
07:33 EDTCELGAlliqua announces licensing agreement with Celgene
Subscribe for More Information
May 11, 2015
12:51 EDTACTOn The Fly: Top stock stories at midday
Subscribe for More Information
09:21 EDTACTOn The Fly: Pre-market Movers
Subscribe for More Information
09:00 EDTACTActavis says committed to utilizing FCF to accelerate debt repayment
Subscribe for More Information
08:57 EDTACTActavis says 'doing exceptionally well' on cost synergy capture
Subscribe for More Information
08:52 EDTACTActavis sets 'aspirational' FY17 EPS target of $25
Subscribe for More Information
08:48 EDTACTActavis sees sNDA submission for low dosage Linzess in 2016
Subscribe for More Information
06:40 EDTACTActavis sees Eluxadoline, Cariprazine PDUFAs in Q2
Subscribe for More Information
06:37 EDTACTActavis sees 2015 EPS $17.00-$18.50, consensus $17.70
Sees 2015 pro forma revenue $22M-$22.5B, consensus $21.47B. Sees 2015 total net revenue $20.5B-$21B.
06:35 EDTACTActavis reports Q1 EPS $4.30, consensus $3.94
Reports Q1 revenue $4.23B., consensus $4.03B. Reports adjusted EBITDA of $1.78B compared to $860M last year. Results include the contribution from Allergan businesses for the period following the close on March 17.
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use